The news comes after officials announced in March last year that Polish biotechnology firm Mabion had struck a deal with US drug maker Novavax to produce a COVID-19 vaccine.
Mabion has now launched production of the key active ingredient of Novavax's soon-to-be-marketed Nuvaxovid shot in a project co-financed by the Polish government, and is thinking of opening a second production line to increase output, euractiv.pl reported.
The new vaccine is poised to enter the EU market later this month, following marketing authorisation from the European Commission.
The EU executive in December granted conditional marketing approval to the Nuvaxovid COVID‑19 vaccine developed by Novavax, the fifth COVID-19 vaccine authorised for use in adults across the 27-nation European Union.
Novavax is set to deliver up to 100 million doses of the vaccine to EU member states.
The product's third-stage clinical trials have shown Nuvaxovid to be 90.4 percent effective in preventing a severe course of COVID-19.
(pmi/gs)
Source: euractiv.pl, ec.europa.eu